Published: September 2021
The drive within life sciences to improve patient safety and product quality, and provide value to society, while reducing costs requires constant and effective innovation. However, because the pharmaceutical industry operates in a highly regulated sector, some practitioners may apply unthinking, prescriptive, and rigid approaches that are not commensurate to the needs of the process, the nature of the system, and the real risk to the product and the patient.
To get more information about this Guidance Document, please visit the ISPE global site.or contact ISPE Shanghai by email at email@example.com.
This Guidance Document is currently not available in Chinese.
Guidance Document License Agreement
The contents of ISPE’s guidance documents, both printed and digital, are protected by law and intended solely for the personal non-commercial use of the individual purchaser. Reproduction of multiple copies of these materials, in whole or in part, for the purposes of commercial distribution is prohibited. Membership discounts are available only to current members and are intended for individual use of the guides, not for resale.